GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arno Therapeutics Inc (OTCPK:ARNI) » Definitions » Other Cash Payments from Operating Activities

Arno Therapeutics (Arno Therapeutics) Other Cash Payments from Operating Activities


View and export this data going back to 2006. Start your Free Trial

What is Arno Therapeutics Other Cash Payments from Operating Activities?

Other Cash Payments from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

Arno Therapeutics (Arno Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arno Therapeutics Inc (OTCPK:ARNI) » Definitions » Other Cash Payments from Operating Activities
Comparable Companies
PLPL BTHE WIZP TSXV:VXL OHEL:FITBIO ENTB ASX:ACL XSAT:PANION PTEO CRXM WAR:BLR LSE:AOR TNTY LSE:PEBI TSXV:PBS WAR:SCS ADYNF SOAN WAR:PFM FPMI
Traded in Other Exchanges
N/A
Address
200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Website
http://www.arnothera.com
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
Executives
S Donald Sussman other: See Footnote 1 888 EAST LAS OLAS BLVD, SUITE 710, FORT LAUDERDALE FL 33301
David M Tanen director, officer: Secretary TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Arie Belldegrun director UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Alexander A Zukiwski director, officer: Chief Executive Officer & CMO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jay Moorin director C/O PROQUEST INVESTMENTS, L.P, 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Lawrence A Kenyon officer: Chief Financial Officer C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Glenn R. Mattes director, officer: President & CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Wexford Gp Llc other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Joseph Jacobs other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Capital Lp other: No longer own 10% of Issuer 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Charles E Davidson other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Ran Nussbaum 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Brian Lenz officer: Chief Financial Officer 65 COMMERCE WAY, HACKENSACK NJ 07601